| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1995;110:368-373
© 1995 Mosby, Inc.
GENERAL THORACIC SURGERY |
Toronto, Ontario, Canada, Nedlands, Western Australia, and Milwaukee, Wis.
From the Division of Thoracic Surgery, Mt. Sinai Hospital and the University of Toronto, Toronto, Canada,a the Department of Pharmacology, University of Western Australia, Nedlands, Western Australia,b and the Department of Physiology, Medical College of Wisconsin, Milwaukee, Wis.c
Received for publication Aug. 12, 1994. Accepted for publication Nov. 28, 1994. Address for reprints: M. R. Johnston, MD, 600 University Ave., Suite 643, Toronto, Ontario, Canada M5G 1X5.
Abstract
Eight patients with metastatic sarcoma to the lung (n= 4) or diffuse bronchioloalveolar carcinoma of the lung (n= 4) underwent isolated lung perfusion with chemotherapy in a pilot study. Ages ranged from 18 to 60 years and half were female. The left lung was perfused in three patients (single lung perfusion) and both lungs in five patients (total lung perfusion). Perfusions ranged from 45 to 60 minutes at ambient or normothermic temperatures. One patient received perfusion at moderate hyperthermia (40° C). Escalating doses of doxorubicin (1 to 10µg/ml perfusate) was used in six patients, whereas two received cisplatin (14 and 20µg/ml perfusate). There were two major complications and no objective responses. The isolated perfusion systems gave excellent separation between systemic and pulmonary circulations with zero to 15% of the measured peak drug concentration of the pulmonary perfusate detected in the systemic circulation. Drug concentrations in normal lung and tumor generally increased with higher drug dosages and drug was detectable in mediastinal lymph nodes of three out of four patients in whom sampling was done. Isolated lung perfusion with chemotherapy can be done safely in patients with lung malignancies and evidence suggests that higher drug dosages should be well tolerated. (J THORACCARDIOVASC SURG1995;110:368-73)
This article has been cited by other articles:
|
|
 |
|
  C. Cheng, A. Haouala, T. Krueger, F. Mithieux, J. Y. Perentes, S. Peters, L. A. Decosterd, and H.-B. Ris Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 635 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yan, C. Cheng, A. Haouala, T. Krueger, J.-P. Ballini, S. Peters, L. A. Decosterd, I. Letovanec, H.-B. Ris, and S. Andrejevic-Blant Distribution of Free and Liposomal Doxorubicin After Isolated Lung Perfusion in a Sarcoma Model Ann. Thorac. Surg., April 1, 2008; 85(4): 1225 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel Isolated lung perfusion and related techniques for the treatment of pulmonary metastases Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Biancosino, M. Albert, and A. Linder Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model high-dose therapy during isolated perfusion without acute toxic lung edema Interactive CardioVascular and Thoracic Surgery, October 1, 2007; 6(5): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Krueger, A. Kuemmerle, S. Andrejevic-Blant, H. Yan, Y. Pan, J.-P. Ballini, W. Klepetko, L. A. Decosterd, R. Stupp, and H.-B. Ris Antegrade Versus Retrograde Isolated Lung Perfusion: Doxorubicin Uptake and Distribution in a Sarcoma Model Ann. Thorac. Surg., December 1, 2006; 82(6): 2024 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Grootenboers, J. Heeren, B. P Van putte, J. M. Hendriks, W. J Van boven, P. E. Van schil, and F. M. Schramel Isolated lung perfusion for pulmonary metastases, a review and work in progress Perfusion, September 1, 2006; 21(5): 267 - 276. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Krueger, A. Kuemmerle, M. Kosinski, A. Denys, L. Magnusson, R. Stupp, A. B. Delaloye, W. Klepetko, L. Decosterd, H.-B. Ris, et al. Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: Evaluation of different cytostatic lung perfusion techniques in a porcine model. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 304 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jinbo, K. Ueda, Y. Kaneda, M. Sudo, T.-S. Li, and K. Hamano Video-assisted transcatheter lung perfusion regional chemotherapy Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1079 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Romijn, J. M.H. Hendriks, B. P. Van Putte, J. Weyler, G. Guetens, G. De Boeck G, E. A. De Bruijn, and P. E.Y. Van Schil Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1083 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. H. Hendriks, M. J. J. H. Grootenboers, F. M. N. H. Schramel, W. J. van Boven, B. Stockman, H. T. M. ter Beek, C. A. Seldenrijk, P. ten Broecke, C. A. J. Knibbe, P. Slee, et al. Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial Ann. Thorac. Surg., December 1, 2004; 78(6): 1919 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. F.W. Franke, T. Wittwer, M. Lessel, K. Liebing, M. Albert, V. Becker, H. Schubert, and T. Wahlers Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: I. Influence of perfusion pressure and hyperthermia on functional and morphological lung integrity Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. F.W. Franke, T. Wittwer, M. Kaluza, M. Albert, V. Becker, M. Roskos, M. Lessel, and T. Wahlers Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 800 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, G. De Boeck, G. Guetens, E. De Bruijn, and P. E. Y. Van Schil Pharmacokinetics after pulmonary artery perfusion with gemcitabine Ann. Thorac. Surg., October 1, 2003; 76(4): 1036 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsuchiya, Y. Kanazawa, M. E. Abdel-Wanis, N. Asada, S. Abe, K. Isu, T. Sugita, and K. Tomita Effect of Timing of Pulmonary Metastases Identification on Prognosis of Patients With Osteosarcoma: The Japanese Musculoskeletal Oncology Group Study J. Clin. Oncol., August 15, 2002; 20(16): 3470 - 3477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schroder, S. Fisher, A. C. Pieck, A. Muller, U. Jaehde, H. Kirchner, A. Haverich, and P. Macchiarini Technique and results of hyperthermic (41{degrees}C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 41 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schneider, S. Kampfer, C. Loddenkemper, T. Foitzik, and H. J. Buhr Chemoembolization of the Lung Improves Tumor Control in a Rat Model Clin. Cancer Res., July 1, 2002; 8(7): 2463 - 2468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Murdter, G. Friedel, J. T. Backman, M. McClellan, M. Schick, M. Gerken, K. Bosslet, P. Fritz, H. Toomes, H. K. Kroemer, et al. Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by beta -Glucuronidase J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 223 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schrump, S. Zhai, D. M. Nguyen, T. S. Weiser, B. A. Fisher, R. E. Terrill, B. M. Flynn, P. H. Duray, and W. D. Figg Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 686 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Johnston, J. B.M. Mullen, M. E. Pagura, and R. B. Howard Validation of an orthotopic model of human lung cancer with regional and systemic metastases Ann. Thorac. Surg., April 1, 2001; 71(4): 1120 - 1125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vail, and M. G. Kris Development of Inhalational Agents for Oncologic Use J. Clin. Oncol., March 15, 2001; 19(6): 1839 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Burt, D. Liu, A. Abolhoda, H. M. Ross, Y. Kaneda, E. Jara, E. S. Casper, R. J. Ginsberg, and M. F. Brennan Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial Ann. Thorac. Surg., May 1, 2000; 69(5): 1542 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Hershey, I. D. Kurzman, L. J. Forrest, C. A. Bohling, M. Stonerook, M. E. Placke, A. R. Imondi, and D. M. Vail Inhalation Chemotherapy for Macroscopic Primary or Metastatic Lung Tumors: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model Clin. Cancer Res., September 1, 1999; 5(9): 2653 - 2659. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
